New Cases of Hypochromic Microcytic Anemia Due to Mutations in the SLC11A2 Gene and Functional Characterization of the G75R Mutation

• Published in: International journal of molecular sciences Vol. 23; no. 8; p. 4406
• Main Authors: Romero-Cortadellas, Lídia, Hernández, Gonzalo, Ferrer-Cortès, Xènia, Zalba-Jadraque, Laura, Fuster, José Luis, Bermúdez-Cortés, Mar, Galera-Miñarro, Ana María, Pérez-Montero, Santiago, Tornador, Cristian, Sánchez, Mayka
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 15-04-2022; MDPI
• Subjects: Anemia; Anemia - genetics; Anemia, Hypochromic - genetics; Animals; Bone marrow; Cell lines; Divalent metal transporter-1; DMT1; Endocytosis; Endosomes; EPO; Erythropoietin; Hemoglobin; Homeostasis; Humans; Intestine; Iron; Iron - metabolism; iron overload; Iron Overload - metabolism; Liver; Localization; Lysosomes; Magnetic resonance imaging; Mammals - metabolism; microcytic anemia; Mutation; Pathogenicity; Patients; Protein turnover; Proteins; SLC11A2; Splicing; Transferrin; Transferrins; iron overload; microcytic anemia; mutation; EPO; DMT1; SLC11A2
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms23084406

Divalent metal-iron transporter 1 (DMT1) is a mammalian iron transporter encoded by the SLC11A2 gene. DMT1 has a vital role in iron homeostasis by mediating iron uptake in the intestine and kidneys and by recovering iron from recycling endosomes after transferrin endocytosis. Mutations in SLC11A2 cause an ultra-rare hypochromic microcytic anemia with iron overload (AHMIO1), which has been described in eight patients so far. Here, we report two novel cases of this disease. The first proband is homozygous for a new SLC11A2 splicing variant (c.762 + 35A > G), becoming the first ever patient reported with a SLC11A2 splicing mutation in homozygosity. Splicing studies performed in this work confirm its pathogenicity. The second proband harbors the previously reported DMT1 G75R mutation in homozygosis. Functional studies with the G75R mutation in HuTu 80 cells demonstrate that this mutation results in improper DMT1 accumulation in lysosomes, which correlates with a significant decrease in DMT1 levels in patient-derived lymphoblast cell lines (LCLs). We also suggest that recombinant erythropoietin would be an adequate therapeutic approach for AHMIO1 patients as it improves their anemic state and may possibly contribute to mobilizing excessive hepatic iron.